OBJECTIVE: To assess the humoral immune response to low-dose AS03-adjuvanted and standard-dose nonadjuvanted 2009 pandemic H1N1 influenza A vaccine in HIV-infected aviremic individuals receiving antiretroviral therapy and in uninfected individuals. DESIGN: A three-arm study. SETTING: Two clinics: one at the National Institutes of Health in Bethesda, Maryland, USA; and the other at the Maple Leaf Medical Clinic in Toronto, Ontario, Canada. PARTICIPANTS: HIV-infected and HIV-uninfected adults. INTERVENTION: Single intramuscular 15 μg dose of the monovalent inactivated 2009 pandemic H1N1 influenza A vaccine without adjuvant or 3.75 μg dose of the same strain with adjuvant AS03. MAIN OUTCOMES: Immunogenicity, as measured by hemagglutination inhibition (HAI) antibody titers and vaccine-specific memory B-cell responses. RESULTS: A total of 74 participants were enrolled. Twenty-one HIV-infected individuals received the low-dose adjuvanted 2009 pandemic H1N1 influenza A vaccine. Twenty-nine HIV-infected and 24 HIV-uninfected individuals received the standard-dose nonadjuvanted vaccine. There were no significant differences in antibody responses at 9 weeks postvaccination among the three groups studied. However, the IgG memory B-cell response against the vaccine was significantly higher in the HIV-infected group that received the low-dose adjuvanted vaccine when compared to the HIV-infected and uninfected groups that received the standard-dose nonadjuvanted vaccine. Conclusions remained unchanged after regression adjustment for age, gender, CD4 T-cell count, and baseline HAI titer. CONCLUSION: These data suggest that adjuvants could be used to expand coverage through dose sparing and improve humoral immune responses in immunocompromised individuals.
OBJECTIVE: To assess the humoral immune response to low-dose AS03-adjuvanted and standard-dose nonadjuvanted 2009 pandemic H1N1influenza A vaccine in HIV-infected aviremic individuals receiving antiretroviral therapy and in uninfected individuals. DESIGN: A three-arm study. SETTING: Two clinics: one at the National Institutes of Health in Bethesda, Maryland, USA; and the other at the Maple Leaf Medical Clinic in Toronto, Ontario, Canada. PARTICIPANTS: HIV-infected and HIV-uninfected adults. INTERVENTION: Single intramuscular 15 μg dose of the monovalent inactivated 2009 pandemic H1N1influenza A vaccine without adjuvant or 3.75 μg dose of the same strain with adjuvant AS03. MAIN OUTCOMES: Immunogenicity, as measured by hemagglutination inhibition (HAI) antibody titers and vaccine-specific memory B-cell responses. RESULTS: A total of 74 participants were enrolled. Twenty-one HIV-infected individuals received the low-dose adjuvanted 2009 pandemic H1N1influenza A vaccine. Twenty-nine HIV-infected and 24 HIV-uninfected individuals received the standard-dose nonadjuvanted vaccine. There were no significant differences in antibody responses at 9 weeks postvaccination among the three groups studied. However, the IgG memory B-cell response against the vaccine was significantly higher in the HIV-infected group that received the low-dose adjuvanted vaccine when compared to the HIV-infected and uninfected groups that received the standard-dose nonadjuvanted vaccine. Conclusions remained unchanged after regression adjustment for age, gender, CD4 T-cell count, and baseline HAI titer. CONCLUSION: These data suggest that adjuvants could be used to expand coverage through dose sparing and improve humoral immune responses in immunocompromised individuals.
Authors: A Amendola; A Boschini; D Colzani; G Anselmi; A Oltolina; R Zucconi; M Begnini; S Besana; E Tanzi; A R Zanetti Journal: J Med Virol Date: 2001-12 Impact factor: 2.327
Authors: Angela Malaspina; Susan Moir; Susan M Orsega; Joshua Vasquez; Natalie J Miller; Eileen T Donoghue; Shyamasundaran Kottilil; Misrak Gezmu; Dean Follmann; Galina M Vodeiko; Roland A Levandowski; JoAnn M Mican; Anthony S Fauci Journal: J Infect Dis Date: 2005-03-24 Impact factor: 5.226
Authors: Susan Moir; Clarisa M Buckner; Jason Ho; Wei Wang; Jenny Chen; Amy J Waldner; Jacqueline G Posada; Lela Kardava; Marie A O'Shea; Shyam Kottilil; Tae-Wook Chun; Michael A Proschan; Anthony S Fauci Journal: Blood Date: 2010-09-13 Impact factor: 22.113
Authors: Michael J Ombrello; Elaine F Remmers; Guangping Sun; Alexandra F Freeman; Shrimati Datta; Parizad Torabi-Parizi; Naeha Subramanian; Tom D Bunney; Rhona W Baxendale; Marta S Martins; Neil Romberg; Hirsh Komarow; Ivona Aksentijevich; Hun Sik Kim; Jason Ho; Glenn Cruse; Mi-Yeon Jung; Alasdair M Gilfillan; Dean D Metcalfe; Celeste Nelson; Michelle O'Brien; Laura Wisch; Kelly Stone; Daniel C Douek; Chhavi Gandhi; Alan A Wanderer; Hane Lee; Stanley F Nelson; Kevin V Shianna; Elizabeth T Cirulli; David B Goldstein; Eric O Long; Susan Moir; Eric Meffre; Steven M Holland; Daniel L Kastner; Matilda Katan; Hal M Hoffman; Joshua D Milner Journal: N Engl J Med Date: 2012-01-11 Impact factor: 91.245
Authors: John S Tsang; Pamela L Schwartzberg; Yuri Kotliarov; Angelique Biancotto; Zhi Xie; Ronald N Germain; Ena Wang; Matthew J Olnes; Manikandan Narayanan; Hana Golding; Susan Moir; Howard B Dickler; Shira Perl; Foo Cheung Journal: Cell Date: 2014-04-10 Impact factor: 41.582
Authors: Karen K Yam; Erica Gipson; Marina Klein; Sharon Walmsley; David Haase; Scott Halperin; David Scheifele; Brian J Ward; Curtis Cooper Journal: J Clin Immunol Date: 2014-05-14 Impact factor: 8.317
Authors: B Steffens; T Kümmerle; S Koch; A Birtel; C Schwarze-Zander; J Emmelkamp; W V Kern; C Hertenstein; C Wyen; C Lehmann; O A Cornely; J Rockstroh; Gerd Fätkenheuer Journal: Eur J Med Res Date: 2011-07-25 Impact factor: 2.175
Authors: Claire-Anne Siegrist; Christian van Delden; Michael Bel; Christophe Combescure; Cécile Delhumeau; Matthias Cavassini; Olivier Clerc; Sara Meier; Karine Hadaya; Paola M Soccal; Sabine Yerly; Laurent Kaiser; Bernard Hirschel; Alexandra Calmy Journal: PLoS One Date: 2012-07-27 Impact factor: 3.240